Illustrative image – not actual.The new unit, which will commence operations from November 2019, is equipped with modern technologies and equipment which will ensure robust functioning and product manufacturing.
Of the total investment of Rs 4,000 crore, Rs 3,200 crore has already been invested. The new manufacturing unit seeks to create more job opportunities and increase
SII’s market share in the international market. It will maximise the production of vaccines such as HPV and TDAP in addition to Thermostable Rotasiil along with monoclonal antibodies like Trastuzumab (Herceptin) and Ustekinumab (Stelara). Each of the vaccines will help protect and provide a healthy life to recipients.
